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Abstract
Background: Sphingolipids are increasingly recognized to play a role in insulin resistance and diabetes. Recently
we reported significant elevations of 1-deoxysphingolipids (1-deoxySL) - an atypical class of sphingolipids in patients
with metabolic syndrome (MetS) and diabetes type 2 (T2DM). It is unknown whether 1-deoxySL in patients with
diabetes type 1 (T1DM) are similarly elevated.
Findings: We analyzed the long chain base profile by LC-MS after hydrolyzing the N-acyl and O-linked headgroups
in plasma from individuals with T1DM (N= 27), T2DM (N= 30) and healthy controls (N =23). 1-deoxySLs were
significantly higher in the groups with T2DM but not different between T1DM and controls. In contrast to patients
with T2DM, 1-deoxSL levels are not elevated in T1DM.
Conclusions: Our study indicates that the 1-deoxySL formation is not per-se caused by hyperglycemia but rather
specifically associated with metabolic changes in T2DM, such as elevated triglyceride levels.
Keywords: Atypical sphingolipids, Biomarker, Deoxysphingolipids, Metabolic syndrome, Type 2 diabetes mellitus,
Type 1 diabetes mellitus
Introduction
Sphingolipids are bioactive lipids that contribute to plasma
membrane and plasma lipoprotein formation. There is
increasing evidence that sphingolipids play a role in insulin
resistance and diabetes [1,2]. They are derived from the
aliphatic amino alcohol sphingosine, which is typically a
C18 long chain (sphingoid) base and formed from the
precursors L-serine and palmitoyl-CoA. This first and rate
liming step in the de-novo synthesis of sphingolipids is
catalyzed by the enzyme serine-palmitoyltransferase (SPT).
Besides the canonical substrates L-serine and palmitoyl-
CoA, SPT is able to metabolize other acyl-CoAs in the
range of C12 to C18 but also alanine and glycine under
certain conditions, which forms a broad spectrum of atyp-
ical sphingoid bases. Approximately 15% of the sphingoli-
pids in human plasma contain an atypical sphingoid base
backbone [2]. In particular, the conjugation of alanine and
glycine forms a class of neurotoxic 1-deoxy-sphingolipids
(1-deoxSL) which lack the C1-OH group of the regular
sphingoid bases. They are therefore neither metabolized
to complex sphingolipids nor degraded by the canonical
catabolic pathway.
Several missense mutations in SPT are associated with
pathologically increased 1-deoxySL levels which causes
the rare inherited sensory neuropathy HSAN1 (hereditary
sensory and autonomic neuropathy type 1) [3,4]. HSAN1
is a length dependent axonopathy, predominantly affect-
ing the distal extremities and characterized by progressive
sensory loss giving rise to painless skin ulcers and bone
infections [5]. Physiologically, the de-novo sphingolipid
synthesis represents a metabolic cross point which in-
terconnects fatty acid, amino acid and thereby indirectly
also carbohydrate metabolism. The observation that
SPT is able to metabolize a variety of acyl-CoA and AA
substrates indicates that alterations in these pathways
might also be reflected by changes in the SPT product
pattern.
We previously showed that 1-deoxySL levels are signifi-
cantly elevated in plasma of patients with metabolic syn-
drome (MetS) and type 2 diabetes (T2DM) [6-8]. Here we
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profile of individuals with type 1 diabetes (T1DM), T2DM
and healthy controls.
Methods
Study participants
Blood samples were obtained through sample discards
from the hospital HbA1c laboratory. We limited the
sample collection to patients being seen in the MGH
Diabetes Center with blood draw ICD9 codes of 250.xx,
and non-Diabetes Center patient samples where HbA1c
blood sample was obtained for screening purposes (V700)
and where the HbA1c value was <5.4%. Chart review was
performed on all patients on whom discarded samples
were obtained to assess basic demographic details (age,
gender), type of diabetes, duration of diabetes, co-morbid
conditions including hypertension, dyslipidemia, diabetic
neuropathy, insulin and statin medication use, recent
blood pressure, laboratory test results (total cholesterol,
triglycerides, LDL, HDL, ALT, AST, serum creatinine),
and use of tobacco and alcohol. Operational definitions
are provided in (Additional file 1). A chart review form
was used to standardize data collection, and the data
was blinded immediately after collection. Age-matched
healthy controls were defined by normal glucose toler-
ance, normal blood pressure, normal lipids variable, and
normal waist circumference. The protocol was approved
by the Partners Healthcare’ Institutional Review Board,
and all participants provided written consent.
Quantification of sphingoid bases
Discarded venous blood samples were obtained in EDTA
tubes and stored at 4°C until all clinical laboratory test-
ing was complete. Plasma was obtained after spinning
the samples at 3400 rpm for 15 minutes. Samples were
aliquoted, anonymized and immediately frozen to −80°C.
For sphingoid base analysis the samples were shipped on
dry ice overnight to the University of Zurich. The sphin-
goid base profile was analyzed by Liquid Chromatog-
raphy/Mass Spectrometry (LC-MS) after hydrolyzing the
N-acyl and O-linked headgroups as described earlier [9].
Analyzed sphingoid bases included C16SO, C16SA,
C17SO, C17SA, C18SO, C18SA, C20SO, C18-SA-diene,
1-deoxysphinganine, and 1-deoxysphingosine.
Statistics
The clinical and lipid data were merged and clinical
baseline characteristics and sphingoid base levels com-
pared between groups (controls, T1DM, T2DM) by
univariate and multivariate linear regression models to
control for baseline differences between groups. As some
of the variables measured did not follow a normal distri-
bution, even after log-transformations, non-parametric
tests were used. The Kruskal-Wallis test was used to
compare all three groups, and Mann–Whitney U test
was used for comparisons between two groups for con-
tinuous variables and X2 test for categorical variables.
For multivariate analysis, sphingoid base levels were
log-transformed and a generalized linear model was
used to assess for significant differences between the
groups initially adjusting for age, lipid levels (triglycer-
ides, LDL), serum creatinine, and hypertension as indi-
vidual covariates and building a multivariate model of
variables that remained significant in the initial models
(age, triglycerides, and LDL). A Bonferroni correction
to account for multiple testing in multivariate model
building was applied, with a significance level of 0.05
which corresponds to a p-value of 0.004. All analyses were
performed with SAS statistical software, version 9.3 (SAS
Institute Inc., Cary, North Carolina). The SAS multivariate
linear regression model used was a proc mixed model.
Results
For this study, we analyzed plasma samples from a total of
80 individuals with either T1DM (N=27), T2DM (N=30)
or without diabetes or evidence of metabolic syndrome
(N=23). Unadjusted demographic and clinical character-
istics are shown in Table 1. There were significant differ-
ences between the T1DM and T2DM groups. The T1DM
group was in average younger and had significantly lower
TG and higher HDL cholesterol levels, lower statin use
and a longer disease history. Compared to controls both
groups showed significantly elevated HbA1C levels indi-
cating reoccurring phases of hyperglycemia despite gly-
cemic control. No significant difference in HbA1c was
seen between T1DM and T2DM. Nineteen of the 30
T2DM were on insulin therapy.
The sphingoid bases which are formed in the canonical
SPT reaction (C18SA, C18SO, C18SA-diene) were not
different between the groups although SA-diene was by
trend lower in T2DM and C18SA lower in T1DM com-
pared to controls. For the sphingoid bases with atypical
chain lengths, C16SA turned out to be significantly lower
in T1DM compared to T2DM or controls.
In contrast, 1-deoxySL levels were clearly different
between the 3 groups. As in prior reports, the 1-deoxySLs
(1-deoxysphinganine and 1-deoxysphingosine) were signifi-
c a n t l ye l e v a t e di nT 2 D M .N od i f f e r e n c ei nt h e1 - d e o x S L
levels was seen between T1DM and controls. After con-
trolling for age, TG and LDL, the 1-deoxysphinganine
levels remained significantly elevated in T2DM com-
pared to controls (p=0.003) whereas differences in the
1-deoxysphingosine levels were no longer significant in
t h em u l t i v a r i a t ea n a l y s i s .
Discussion
1-deoxySLs are atypical and neurotoxic products which
are formed by SPT due to the alternate use of L-alanine
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elevated 1-deoxySL levels are formed by mutant forms
of SPT and cause the rare inherited neuropathy HSAN1.
However, 1-deoxySLs are typically present at low levels
in the plasma of healthy individuals and significantly ele-
vated in individuals with MetS and T2DM. This shows
that also normal (wild type) SPT is able to catalyze this
reaction although the reason why increased amount of
these lipids are formed under metabolic conditions is not
yet understood. A possible mechanism could be an in-
creased availability of intracellular alanine in the hypergly-
cemic state. L-serine is formed from 3-phosphoglycerate
whereas L-alanine is converted to pyruvate through ala-
nine aminotransferase (ALT) in a reversible transaminase
reaction. Hence, the precursors for both amino acids
are generated during glycolysis and thereby provide a
functional link between sphingolipid and carbohydrate
metabolism.
In this work we compared the 1-deoxySL levels between
individuals with T1DM, T2DM and healthy controls. In
agreement with our earlier results we confirmed elevated
1-deoxySL in T2DM. However, 1-deoxySL levels were not
increased in T1DM. The fact that glucose and HbA1c
levels were not significantly different between the T1DM
and T2DM groups indicates that hyperglycemia per se is
not a determinant of 1-deoxySL formation. This suggests
that glucose levels do not directly contribute to 1-deoxySL
formation, indicating that other mechanisms are at play.
However, these findings stand in contrast to the observa-
tion that 1-deoxySLs are elevated in plasma and liver of
STZ rats, a T1DM animal model [6].
Alternatively, differences in the 1-deoxySL levels may
be driven by elevated triglyceride levels. In fact, T2DM
but not T1DM is typically associated with elevated TG
levels. The correlation between 1-deoxySL levels and tri-
glycerides has been demonstrated earlier [6], but can also
be seen in the present study where 1-deoxySLs show a sig-
nificant correlation to plasma TGs (see Additional file 2:
Table S1). In contrast, serine-based sphingoid bases
showed a closer correlation to total and LDL cholesterol
levels. A functional link between plasma TG levels and
1-deoxySL formation might also explain why 1-deoxySL
are elevated in the STZ rat model which have, in con-
trast to human T1DM patients, typically a more athero-
genic lipid profile including elevated plasma TG levels.
However, it is not yet clear how elevated plasma TGs
Table 1 Baseline characteristics and results
Type 1 Type 2 Control overall p-value T1 vs. T2
p-value
T2 vs. control
p-value
T1 vs. control
p-value
N 27 30 23 Kruskal-Wallis/Chi-Sq Wilcoxon/Fisher’s Wilcoxon/Fisher’s Wilcoxon/Fisher’s
Age, mean (s.d.) 47 (14.6) 60 (13.6) 43 (15) <0.001 0.001 <0.001 0.4
Male, N (%) 16 (59) 16 (53) 11 (48) 0.7 0.8 0.8 0.6
HbA1c, mean (s.d.) 7.3 (1.3) 7.8 (2) 5.2 (0.3) <0.001 0.4 <0.001 <0.001
TG, mean (s.d.) 70 (33) 145 (84) 84 (35) <0.001 <0.001 0.003 0.1
LDL, mean (s.d.) 87 (27) 83 (35) 116 (44) 0.006 0.8 0.008 0.006
HDL, mean (s.d.) 70 (17) 49 (22) 60 (19) <0.001 <0.001 0.02 0.04
HTN, N (%) 14 (52) 25 (83) 3 (13) <0.001 0.02 <0.001 0.006
SBP, mean (s.d.) 124 (15) 130 (15) 125 (17) 0.2 0.08 0.3 0.8
DBP, mean (s.d.) 72 (8) 74 (8) 76 (12) 0.4 0.4 0.7 0.2
Cr, mean (s.d.) 0.97 (0.4) 0.90 (0.2) 0.91 (0.5) 0.2 0.7 0.2 0.07
Statin, N (%) 14 (52) 23 (77) 2 (9) <0.001 0.06 <0.001 0.002
DM duration, mean (s.d.) 25 (11) 13 (8) 0 <0.001
C16SO, mean (s.d.) 16.9 (4.4) 18.4 (6.0) 19.9 (9.5) 0.8 0.5 0.99 0.6
C16SA, mean (s.d.) 0.26 (0.13) 0.41 (0.19) 0.45 (0.22) <0.001 <0.001 0.6 0.001
C17SO, mean (s.d.) 7.1 (1.6) 7.4 (2.3) 8.5 (3.3) 0.5 0.8 0.4 0.3
C18SAdiene, mean (s.d.) 34.9 (6.4) 30.3 (9.3) 39.3 (11.3) 0.007 0.02 0.006 0.3
C18SO, mean (s.d.) 92.3 (11.2) 87.1 (20.4) 103.9 (25.4) 0.02 0.1 0.01 0.1
C18SA, mean (s.d.) 3.1 (1.0) 2.4 (0.6) 2.9 (1.0) 0.01 0.03 0.3 0.008
C20SO, mean (s.d.) 0.13 (0.02) 0.15 (0.05) 0.14 (0.04) 0.2 0.06 0.2 0.8
C20SA, mean (s.d.) 0.02 (0.004) 0.02 (0.01) 0.02 (0.002) 0.02 0.004 0.3 0.1
doxSA, mean (s.d.) 0.05 (0.02) 0.09 (0.06) 0.05 (0.02) <0.001 <0.001 <0.001 0.5
doxSO, mean (s.d.) 0.12 (0.04) 0.19 (0.11) 0.12 (0.04) 0.002 0.002 0.006 0.9
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not an altered lipid substrate – is at the base of 1-deoxySL
formation. Yet is it unknown how plasma TG result in an
altered use of alanine by SPT. It therefore remains subject
of further studies to see how these two metabolic path-
ways are interrelated.
Additional file
Additional file 1: Operational Definitions.
Additional file 2: Table S1. Pearson Correlation Coefficients.
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